Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone214-474-3103
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$48.83 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) posted its quarterly earnings results on Thursday, February, 28th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.15. The firm had revenue of $14.53 million for the quarter, compared to analyst estimates of $15.58 million. Nuvectra had a negative return on equity of 60.14% and a negative net margin of 91.74%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What guidance has Nuvectra issued on next quarter's earnings?
Nuvectra issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $53.2-53.6 million, compared to the consensus revenue estimate of $52.94 million.Nuvectra also updated its Q4 2018 guidance to EPS.
What price target have analysts set for NVTR?
4 Wall Street analysts have issued 1-year price objectives for Nuvectra's stock. Their predictions range from $18.00 to $27.00. On average, they anticipate Nuvectra's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 78.9% from the stock's current price. View Analyst Price Targets for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.
Has Nuvectra been receiving favorable news coverage?
Media headlines about NVTR stock have been trending positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nuvectra earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the near term.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include AngioDynamics (ANGO), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Axonics Modulation Technologies (AXNX), LeMaitre Vascular (LMAT), SurModics (SRDX), Antares Pharma (ATRS), SI-Bone (SIBN), Anika Therapeutics (ANIK), Accuray (ARAY), GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Pulse Biosciences (PLSE), Inovio Pharmaceuticals (INO) and Vapotherm (VAPO).
What other stocks do shareholders of Nuvectra own?
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)
- Mr. Joseph Paul Hanchin, Pres (Age 57)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)
- Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)
- Mr. Benjamin Tranchina, Chief Technology Officer
Who are Nuvectra's major shareholders?
Nuvectra's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.95%), Dimensional Fund Advisors LP (3.90%), Dimensional Fund Advisors LP (3.90%), Peregrine Capital Management LLC (3.77%), Millennium Management LLC (2.76%) and Northern Trust Corp (1.29%). Company insiders that own Nuvectra stock include Joseph Paul Hanchin, Scott F Drees and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.
Which major investors are selling Nuvectra stock?
NVTR stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Hodges Capital Management Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Northpointe Capital LLC, SG Americas Securities LLC, Acadian Asset Management LLC and Two Sigma Advisers LP. View Insider Buying and Selling for Nuvectra.
Which major investors are buying Nuvectra stock?
NVTR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Peregrine Capital Management LLC, Geode Capital Management LLC, Geode Capital Management LLC, Penn Capital Management Co. Inc., Squarepoint Ops LLC, Northern Trust Corp and Millennium Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $12.44.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $220.19 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.
What is Nuvectra's official website?
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
